V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310004080 | 310001734 | 1.76 | 55 | Not known (9) | 2016-02-04 | 2016-03-23 | Oxaliplatin + Modified de Gramont | N | N | 310019178 | RITUXIMAB |
| 310004081 | 310010388 | 1.51 | 93.6 | Curative (C) | 2017-09-07 | 2017-09-27 | null | N | null | 310019186 | NOT MATCHED |
| 310004082 | 310001735 | 1.86 | 75.3 | Disease modification (D) | 2017-10-13 | 2017-10-16 | CISPLATIN + DOCETAXEL + FLUOROURACIL | 2 | N | 310019190 | EOX |
| 310004083 | 310001735 | 0 | 57.6 | Palliative (P) | 2013-08-05 | 2013-08-05 | Hydroxycarbamide | N | N | 310019190 | MITOMYCIN INTRAVESICULAR |
| 310004084 | 310001736 | 1.68 | 74.4 | Palliative (P) | 2016-08-14 | 2016-08-21 | Bevacizumab+Carbo+Pacliaxel | N | N | 310019192 | CAPECITABINE |
| 310004085 | 310001737 | 0 | 84.9 | Curative (C) | 2014-08-19 | 2014-08-19 | NB HRNBL-1 MOD N7 CAV | 2 | N | 310019193 | NOT MATCHED |
| 310004086 | 310001738 | 1.58 | 80.6 | Palliative (P) | 2017-04-06 | 2017-04-11 | CAPECITABINE + OXALIPLATIN | 02 | N | 310019194 | CAPECITABINE + CISPLATIN |
| 310004087 | 310001739 | null | 91.95 | Palliative (P) | 2013-04-19 | 2013-04-21 | Oxaliplatin + Modified de Gramont | N | N | 310019196 | CISPLATIN + FLUOROURACIL |
| 310004088 | 310006759 | 1.71 | 51.1 | null | 2014-10-31 | 2014-12-01 | CHOEP - 21 days | null | N | 310019203 | CHOEP |
| 310004089 | 310006759 | 1.74 | 70 | Disease modification (D) | 2016-04-26 | 2017-05-13 | Cisplatin +Fluorouracil (3 wk) | null | null | 310019203 | CISPLATIN + ETOPOSIDE |
| 310004090 | 310006759 | null | 51.9 | Neo-adjuvant (N) | null | 2013-05-05 | BEVACIZUMAB + CARBO + PACLITAXEL | 2 | N | 310019203 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 310004091 | 310001740 | 1.62 | 117 | Palliative (P) | null | 2015-11-06 | IPILIMUMAB + NIVOLUMAB | 99 | N | 310019210 | IPILIMUMAB + NIVOLUMAB |
| 310004092 | 310001741 | 1.47 | 80.3 | Curative (C) | 2014-05-24 | 2014-05-25 | STS Non-Rhabdo EpSSG 2005 Ifos Dox | N | null | 310019211 | NOT MATCHED |
| 310004093 | 310006760 | null | null | Neo-adjuvant (N) | 2014-11-27 | 2014-12-11 | Hydroxycarbamide | N | N | 310019213 | VEMURAFENIB |
| 310004094 | 310006760 | null | 50.1 | Palliative (P) | 2014-12-01 | 2014-12-16 | CISPLATIN + FLUOROURACIL | 2 | N | 310019213 | LIPOSOMAL DOXORUBICIN |
| 310004095 | 310001742 | 1.75 | 66.9 | Curative (C) | 2017-08-10 | 2017-09-14 | CHOEP | N | N | 310019216 | CHOEP |
| 310004096 | 310001743 | null | null | Curative (C) | 2016-11-19 | 2016-11-19 | EOX | N | N | 310019219 | LIPOSOMAL DOXORUBICIN |
| 310004097 | 310001743 | 1.74 | 55.4 | Curative (C) | null | 2015-03-30 | Capecitabine + Oxaliplatin 21day | N | N | 310019219 | CAPECITABINE + CISPLATIN |
| 310004098 | 310001743 | null | null | Palliative (P) | 2012-05-11 | 2012-05-20 | Hydroxycarbamide | Y | N | 310019219 | ICON TRIAL |
| 310004099 | 310001744 | null | null | Palliative (P) | 2015-05-06 | 2015-05-06 | CAPECITABINE + OXALIPLATIN | N | null | 310019222 | IMATINIB |
| 310004100 | 310001745 | 0 | 59.6 | null | 2016-05-04 | 2016-05-07 | Capecitabine + Cisplatin | 02 | N | 310019225 | CISPLATIN + FLUOROURACIL |
| 310004101 | 310001746 | 1.72 | 72 | Disease modification (D) | 2010-12-02 | 2014-04-03 | null | N | N | 310019227 | NOT MATCHED |
| 310004102 | 310006762 | 1.61 | 73.6 | Curative (C) | 2013-06-13 | 2013-06-13 | CHOEP - 21 days | Y | null | 310019231 | CHOEP |
| 310004103 | 310009142 | 1.72 | 68.7 | Palliative (P) | 2015-01-14 | 2015-01-30 | Bexarotene | N | N | 310019234 | RITUXIMAB |
| 310004104 | 310009142 | 1.62 | 86 | Disease modification (D) | 2014-07-13 | 2014-07-14 | Hydroxycarbamide | N | N | 310019234 | GEMCITABINE + PACLITAXEL |
| 310004105 | 310001747 | 1.89 | null | Neo-adjuvant (N) | 2017-04-06 | 2017-04-20 | Capecitabine + Cisplatin | N | N | 310019240 | VEMURAFENIB |
| 310004106 | 310001748 | 1.61 | 66.5 | Neo-adjuvant (N) | 2015-03-27 | 2015-04-03 | Mitomycin Intravesical | 2 | N | 310019245 | BEXAROTENE |
| 310004107 | 310001749 | 1.7 | 114.4 | Palliative (P) | 2014-12-25 | 2014-12-25 | Rituximab | N | N | 310019247 | EOX |
| 310004108 | 310001750 | 1.8 | 96.4 | Disease modification (D) | 2011-09-05 | 2015-02-18 | CISPLATIN + FLUOROURACIL | null | null | 310019248 | CISPLATIN + FLUOROURACIL |
| 310004109 | 310001750 | 1.71 | 105 | Not known (9) | 2018-04-24 | 2018-05-09 | Vemurafenib | 02 | N | 310019248 | DACARBAZINE |
| 310004110 | 310001750 | 1.68 | 84 | Curative (C) | 2017-04-01 | 2017-04-01 | ECX | N | N | 310019248 | ECX |
| 310004111 | 310010391 | 1.77 | 69.2 | null | 2017-03-11 | 2017-03-25 | Cisplatin + Docetaxel +Fluorouracil | 02 | N | 310019253 | CAPECITABINE |
| 310004112 | 310010391 | 1.79 | 105.2 | Palliative (P) | null | 2017-07-11 | GEM-P | N | N | 310019253 | ICON TRIAL |
| 310004113 | 310001751 | null | 70.7 | Palliative (P) | 2018-09-22 | 2018-10-28 | Liposomal Doxorubicin (20mg/m2) | 02 | N | 310019260 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 310004114 | 310001752 | 1.6 | 3.7 | Curative (C) | 2015-12-17 | 2015-12-31 | Liposomal Doxorubicin (Caelyx) | 02 | N | 310019261 | LIPOSOMAL DOXORUBICIN |
| 310004115 | 310001753 | 1.59 | null | null | null | 2015-04-30 | Gemcitabine weekly | 99 | N | 310019263 | GEMCITABINE |
| 310004116 | 310001754 | 1.71 | 81.8 | Disease modification (D) | 2017-06-26 | 2017-06-30 | Cisplatin + Docetaxel +Fluorouracil | Y | N | 310019265 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 310004117 | 310001755 | 1.77 | 79.8 | Palliative (P) | 2017-12-10 | 2017-12-11 | IPILIMUMAB + NIVOLUMAB | N | N | 310019266 | IPILIMUMAB + NIVOLUMAB |
| 310004118 | 310001756 | 1.65 | 1.8 | Palliative (P) | 2013-05-06 | 2013-05-07 | Bexarotene | N | N | 310019267 | DACARBAZINE |
| 310004119 | 310001757 | 1.66 | 53 | Disease modification (D) | 2016-12-01 | 2016-12-10 | Liposomal Doxorubicin 40mg/m2 | N | N | 310019268 | IMATINIB |
| 310004120 | 310001758 | 1.77 | 89.6 | Disease modification (D) | 2016-03-07 | 2016-03-10 | Cisplatin + Docetaxel +Fluorouracil | N | N | 310019269 | MITOMYCIN INTRAVESICULAR |
| 310004121 | 310001758 | 1.63 | 76.2 | null | null | 2014-04-11 | Capecitabine + Oxaliplatin 21day | 2 | N | 310019269 | LIPOSOMAL DOXORUBICIN |
| 310004122 | 310001758 | 1.72 | 95 | Curative (C) | 2013-11-09 | 2013-11-16 | Imatinib 400mg | N | N | 310019269 | EOX |
| 310004123 | 310001759 | 1.67 | 80.2 | Palliative (P) | 2013-11-19 | 2013-11-25 | ECX | N | N | 310019274 | PACLITAXEL |
| 310004124 | 310001760 | null | 65.4 | Curative (C) | 2016-04-05 | 2016-04-07 | STS Rhabdomyosarcoma RMS 2005 IVAVV | N | N | 310019275 | NOT MATCHED |
| 310004125 | 310001761 | 1.87 | 69.3 | Curative (C) | 2015-07-22 | 2015-07-28 | Liposomal Doxorubicin 40mg/m2 | N | N | 310019277 | CISPLATIN + ETOPOSIDE |
| 310004126 | 310001762 | 1.8 | 77 | Palliative (P) | 2015-05-28 | 2015-06-03 | ECX | N | N | 310019278 | ECX |
| 310004127 | 310001763 | 1.54 | 56.6 | Neo-adjuvant (N) | 2016-04-15 | 2016-05-03 | Imatinib 400mg | 02 | N | 310019279 | ICON TRIAL |
| 310004128 | 310001764 | 1.74 | null | Not known (9) | 2013-07-20 | 2013-07-26 | ECX | N | null | 310019284 | ECX |
| 310004129 | 310001765 | 1.64 | 0 | Palliative (P) | 2017-07-17 | 2017-07-22 | GEM-P | N | N | 310019285 | LIPOSOMAL DOXORUBICIN |